$130.65
1.25% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US09062X1037
Symbol
BIIB
Sector
Industry

Biogen Stock price

$130.65
+7.49 6.08% 1M
-19.38 12.92% 6M
-22.27 14.56% YTD
-103.19 44.13% 1Y
-147.84 53.09% 5Y
-227.00 63.47% 10Y
+98.60 307.71% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-1.66 1.25%
ISIN
US09062X1037
Symbol
BIIB
Sector
Industry

Key metrics

Market capitalization $19.39b
Enterprise Value $23.09b
P/E (TTM) P/E ratio 13.11
EV/FCF (TTM) EV/FCF 10.06
EV/Sales (TTM) EV/Sales 2.35
P/S ratio (TTM) P/S ratio 1.98
P/B ratio (TTM) P/B ratio 1.14
Revenue growth (TTM) Revenue growth 1.59%
Revenue (TTM) Revenue $9.82b
EBIT (operating result TTM) EBIT $2.58b
Free Cash Flow (TTM) Free Cash Flow $2.30b
Cash position $2.60b
EPS (TTM) EPS $10.09
P/E forward 12.38
P/S forward 2.09
EV/Sales forward 2.49
Short interest 3.35%
Show more

Create a Free Account to create an Biogen alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Biogen Stock Analysis

Unlock Scores for Free

Analyst Opinions

37 Analysts have issued a Biogen forecast:

18x Buy
49%
19x Hold
51%

Analyst Opinions

37 Analysts have issued a Biogen forecast:

Buy
49%
Hold
51%

Financial data from Biogen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
9,816 9,816
2% 2%
100%
- Direct Costs 2,398 2,398
1% 1%
24%
7,419 7,419
2% 2%
76%
- Selling and Administrative Expenses 2,380 2,380
6% 6%
24%
- Research and Development Expense 2,000 2,000
14% 14%
20%
3,002 3,002
26% 26%
31%
- Depreciation and Amortization 420 420
56% 56%
4%
EBIT (Operating Income) EBIT 2,582 2,582
22% 22%
26%
Net Profit 1,479 1,479
27% 27%
15%

In millions USD.

Don't miss a Thing! We will send you all news about Biogen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biogen Stock News

Neutral
GlobeNewsWire
2 days ago
BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moder...
Neutral
Seeking Alpha
3 days ago
Biogen Inc. (NASDAQ:BIIB ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:40 AM ET Company Participants Robin C. Kramer - Executive VP & CFO Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Great.
Neutral
GlobeNewsWire
11 days ago
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors.
More Biogen News

Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Head office United States
CEO Christopher Viehbacher
Employees 7,605
Founded 1978
Website www.biogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today